– Early Evidence of Safety and Impressive Anti-Tumor Activity of Bria-IMT™- BERKELEY, Calif. and VANCOUVER, British Columbia, April 10, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it has been selected to present a late-breaking poster presentation at the …

BERKELEY, Calif. and VANCOUVER, British Columbia, April 3, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the acceptance of a manuscript describing the novel mechanism of action of the Company’s lead product candidate, Bria-IMT™. The findings detailed in …

BERKELEY, Calif. and VANCOUVER, British Columbia, March 27, 2018 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that the Company has completed both its previously announced brokered and non-brokered private placement financings. BriaCell completed a non-brokered private placement …

BERKELEY, Calif. and VANCOUVER, British Columbia, March 14, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it has engaged Akari Health, a leading health-care focused social media marketing company, to improve awareness of its lead product candidate, Bria-IMT™, as a …

BERKELEY, Calif. and VANCOUVER, British Columbia, March 07, 2018 –BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that it expects to enter into a securities purchase agreement of convertible notes with a leading group of Institutional and Family Office funds focused …

BERKELEY, Calif. and VANCOUVER, British Columbia, March 1, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that Dr. Bill Williams, BriaCell’s President & CEO, has been invited to present at Precision Breast Cancer Conference, a global Pharma R&D summit, in Boston, …

BERKELEY, Calif. and VANCOUVER, British Columbia, February 7, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be attending BIO CEO & Investor Conference 2018. The conference will be held February 12-13, 2018 at New York Marriott Marquis Hotel …

BERKELEY, Calif. and VANCOUVER, British Columbia, February 6, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the opening of a new clinical site, Jefferson Breast Care Center in Philadelphia, PA, and the appointment of Dr. Saveri Bhattacharya, a …

– Further Investigation on Mechanism of Action of its Lead Drug Candidate, Bria-IMT™, at AACR event – BERKELEY, Calif. and VANCOUVER, British Columbia, February 5, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will present a poster on the mechanism of action …